Q2 Earnings Estimate for ProKidney Issued By HC Wainwright

ProKidney Corp. (NASDAQ:PROK) – Equities researchers at HC Wainwright issued their Q2 2026 EPS estimates for ProKidney in a research report issued on Thursday, March 19th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.13) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for ProKidney’s Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.66) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at ($0.34) EPS.

Several other research analysts have also commented on the company. Jefferies Financial Group raised ProKidney to a “strong-buy” rating in a research report on Wednesday, March 18th. Wall Street Zen lowered shares of ProKidney from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

ProKidney Stock Performance

ProKidney stock opened at $1.94 on Monday. The company has a market capitalization of $583.61 million, a P/E ratio of -3.73 and a beta of 1.75. ProKidney has a fifty-two week low of $0.46 and a fifty-two week high of $7.13. The stock has a 50-day simple moving average of $2.14 and a 200-day simple moving average of $2.42.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings data on Wednesday, March 18th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.00 million.

Institutional Trading of ProKidney

Hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new position in ProKidney in the 3rd quarter valued at $4,734,000. Artia Global Partners LP acquired a new stake in shares of ProKidney during the 4th quarter valued at approximately $4,118,000. JPMorgan Chase & Co. lifted its position in shares of ProKidney by 3,024.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company’s stock valued at $988,000 after acquiring an additional 1,615,243 shares during the period. Hennion & Walsh Asset Management Inc. boosted its position in ProKidney by 63.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 1,503,886 shares of the company’s stock worth $3,369,000 after purchasing an additional 583,983 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in ProKidney by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 1,197,530 shares of the company’s stock valued at $2,684,000 after purchasing an additional 100,748 shares during the last quarter. 51.59% of the stock is owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.